Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2092-2097

  Rajendran, Ranjith ^a   Mowat, Eilidh ^a   McCulloch, Elaine ^b   Lappin, David F ^a   Jones, Brian ^c   Lang, Sue ^d   Majithiya, Jayesh B ^e   Warn, Peter ^e   Williams, Craig ^b   Ramage, Gordon ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; MESSENGER RNA; VORICONAZOLE;

AFUMDR4 GENE; ANIMAL EXPERIMENT; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BIOFILM; CONTROLLED STUDY; DRUG MEGADOSE; FUNGAL GENOME; FUNGAL STRAIN; GENE EXPRESSION; LOW DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TIME; UPREGULATION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; BIOFILMS; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 79955544138     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01189-10     Document Type: Article

References (38)

1. Andes, D., et al. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-6031.
2. Bueid, A., et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
3. Cannon, R. D., et al. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291-321.
4. da Silva Ferreira, M. E., et al. 2004. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48:4405-4413.
5. da Silva Ferreira, M. E., et al. 2006. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr. Genet. 50:32-44.
6. Denning, D. W., R. M. Tucker, L. H. Hanson, and D. A. Stevens. 1989. Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86:791-800.
7. Henry, K. W., M. C. Cruz, S. K. Katiyar, and T. D. Edlind. 1999. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob. Agents Chemother. 43:1968-1974.
8. Howard, S. J., et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
9. Kaneko, Y., et al. 2010. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med. Mycol. 48:606-612.
10. Lass-Flörl, C., et al. 2003. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. Int. J. Antimicrob. Agents 21:229-233.
11. Lepak, A., J. Nett, L. Lincoln, K. Marchillo, and D. Andes. 2006. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. Antimicrob. Agents Chemother. 50:1311-1319.
12. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
13. Lomovskaya, O., et al. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.
14. Loussert, C., et al. 2010. In vivo biofilm composition of Aspergillus fumigatus. Cell Microbiol. 12:405-410.
15. Mateus, C., S. A. Crow, Jr., and D. G. Ahearn. 2004. Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob. Agents Chemother. 48:3358-3366.
16. Mellado, E., et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
17. Meneau, I., and D. Sanglard. 2005. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med. Mycol. 43(Suppl. 1):S307-S311.
18. Morschhäuser, J. 2010. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet. Biol. 47:94-106.
19. Mosquera, J., and D. W. Denning. 2002. Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46:556-557.
20. Mowat, E., J. Butcher, S. Lang, C. Williams, and G. Ramage. 2007. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J. Med. Microbiol. 56:1205-1212.
21. Mowat, E., et al. 2008. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J. Antimicrob. Chemother. 62:1281-1284.
22. Mowat, E., C. Williams, B. Jones, S. McChlery, and G. Ramage. 2009. The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm? Med. Mycol. 47:(Suppl. 1)S120-S126.
23. Mukherjee, P. K., J. Chandra, D. M. Kuhn, and M. A. Ghannoum. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340.
24. Nascimento, A. M., et al. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726.
25. Nett, J. E., K. Crawford, K. Marchillo, and D. R. Andes. 2010. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54:3505-3508.
26. Nett, J. E., A. J. Lepak, K. Marchillo, and D. R. Andes. 2009. Time course global gene expression analysis of an in vivo Candida biofilm. J. Infect. Dis. 200:307-313.
27. Nierman, W. C., et al. 2005. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 438:1151-1156.
28. Oren, I., et al. 2006. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 38:127-134.
29. Piddock, L. J. 2006. Multidrug-resistance efflux pumps-not just for resistance. Nat. Rev. Microbiol. 4:629-636.
30. Raad, I. I., et al. 2008. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:496-503.
31. Ramage, G., S. Bachmann, T. F. Patterson, B. L. Wickes, and J. L. Lopez-Ribot. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49:973-980.
32. Sambatakou, H., B. Dupont, H. Lode, and D. W. Denning. 2006. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am. J. Med. 119:527, e17-e24.
33. Snelders, E., A. Karawajczyk, G. Schaftenaar, P. E. Verweij, and W. J. Melchers. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54:2425-2430.
34. Snelders, E., et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
35. van de Sande, W. W., M. Tavakol, W. van Vianen, and I. A. Bakker-Woudenberg. 2010. The effects of antifungal agents to conidial and hyphal forms of Aspergillus fumigatus. Med. Mycol. 48:48-55.
36. Wakiec, R., et al. 2007. Voriconazole and multidrug resistance in Candida albicans. Mycoses 50:109-115.
37. Warn, P. A., et al. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58:1198-1207.
38. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.